DiaMedica to Present at 16th Annual BIO CEO & Investor Conference

DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company,
announced today that Mr. Rick Pauls, Chief Executive Officer, will provide a
overview of the Company at the 16th annual BIO-CEO & Investor conference on
Tuesday February 11, 2014 at 3:00 pm EST, at the Waldorf Astoria Hotel in New
York. The conference is hosted by the Biotechnology Industry Organization and is
the largest independent investor conference focused on established and emerging
publicly traded and select private biotech companies.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Rick Pauls
Chairman & CEO
DiaMedica Inc.
One Carlson Parkway, Suite 124 , Minneapolis, MN
Phone: 763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024